The Impact of Mitochondrial Dysfunction on Human Bone Cell Metabolism and Remodelling
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Aalborg University Hospital
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Extracellular acidification rate (ECAR) (mpH/min)
Study Overview
Brief Summary
Cell and mice studies suggest mitochondrial dysfunction may cause altered bone structure.
Hypothesis: Decreased mitochondrial energy production affects bone cell development and activity negatively.
Comparing humans with the mitochondrial DNA variant, m.3243A>G, pathogenic variants in POLG or TWNK genes to healthy controls, the aim is to evaluate the effect of mitochondrial dysfunction on: 1: bone-cell development and -activity in bone marrow stem cells and blood.
2: bone cell metabolism including glucose consumption. 3: bone structure assessed by electron microscopy and μCT scans of bone biopsies.
Detailed Description
Intact mitochondrial activity including adequate energy supplies is vital for metabolic active tissues i.e. skeletal muscle, heart and brain. The human skeleton represent an additional highly metabolically active tissue; nevertheless the significance of the mitochondrial role in human skeletal bone health may be further investigated.
Bone remodelling constitutes the coupled and continuous regenerative process of bone degradation by bone resorbing cells osteoclasts (OC) followed by formation of bone matrix by bone forming osteoblasts (OB). Quantitative imbalance between resorption and formation results in skeletal disorders with low bone mass including osteoporosis, and its increased risk of fragility fractures.
Mitochondria generate cellular energy adenosine triphosphate (ATP) through oxidative phosphorylation process (OXPHOS) in the respiratory chain (RC) with a secondary production of the deleterious by-products free radicals i.e. reactive oxygen species (ROS). Notably, mitochondria hold their own DNA (m.DNA), and RC subunits are encoded by m.DNA and nuclear DNA (n.DNA) genes, respectively. With ageing, deleterious somatic m.DNA mutations accumulate in skeletal muscle and heart, and somatic m.DNA mutations as well as inherited m.DNA or n.DNA mutations may result in mitochondrial dysfunction with impaired ATP production and accumulation of ROS. m.DNA mutations may impair brain, skeletal-, and cardiac muscle function, but the effects on human bone cell metabolism and remodelling are unknown. A recent study of a cohort of young individuals indicates that mitochondrial diseases pose a risk for bone fragility fractures.
Preclinical studies suggest that ATP and ROS regulate bone metabolism. The m.DNA number and mitochondrial activity increase to support differentiation from human skeletal (mesenchymal) stem cells (hMSC) to mature bone forming OBs. Inhibition of mitochondrial activity or increase in ROS levels suppress OB differentiation. Similarly, OCs are rich in mitochondria. Human OC cultures demonstrate that energy supplies for OC differentiation from their progenitors is based on OXPHOS while OC resorption activity relies on glycolysis.
In addition, emerging evidence suggest that metabolic plasticity i.e. regulation of glycolysis, OXPHOS, and pyruvate levels, contribute to regulation of OB and OC differentiation.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Basic Science
- Masking
- None
Masking Description
Participants are masked with anonymized identifier (ID)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Genetic diagnosis with: MT-TL1 m.3243A>G, or POLG variant, het or TWNK variant, het, > 18 years
- •Signed informed consent
- •Inclusion Criteria - controls:
- •Healthy subjects matched on age and gender > 18 years
- •Signed informed consent
Exclusion Criteria
- •Renal (creatinine > 90 µmol/l)
- •Liver dysfunction (AST > 3 times the upper limit)
- •Medical treatment influencing bone metabolism (oral corticosteroid <12 weeks, anti-osteoporosis treatment, sex steroids, anti-convulsants)
- •Pregnancy
- •Excessive consumption of alcohol
- •Treatment with anticoagulants
- •Pre-existing coagulopathy
- •Allergy to lidocaine, morphine or diazepam.
Arms & Interventions
Cases and controls
Clinical assessment, blood samples, dual energy x-ray absorptiometry (DXA) scan, and assessment of bone marrow, and tetracycline labelled bone biopsy
Intervention: Clinical assessment, blood samples, bone marrow and bone biopsy (Diagnostic Test)
Outcomes
Primary Outcomes
Extracellular acidification rate (ECAR) (mpH/min)
Time Frame: Up to 12 weeks
Measurement of ECAR in human bone marrow skeletal (mesenchymal) stem cells (hBM-MSCs), osteoblasts (OB) and osteoclasts (OC)
Growth rate (number of cells)
Time Frame: Up to 12 weeks
Growth rate of of OBs and OCs
Oxygen consumption rate (OCR) (mpMol/min)
Time Frame: Up to 12 weeks
Measurement of OCR in hBM-MSCs, OBs and OCs
Secondary Outcomes
- Histomorphometric(Up to 4 weeks)
- Bone growth rate (µm/day)(Up to 4 weeks)
Investigators
Anja Lisbeth Frederiksen
MD, Ph.D, Clinical Professor
Aalborg University Hospital
